(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2(Date:9/3/2008)... This analysis showed that Multaq(R) (dronedaro... with atrial fibrillation or atrial flutter alread...c therapy, BRIDGEWATER, N.J., Sept. 3 /PRNewswire...of the data from the ATHENA study were presented t...uropean Society of Cardiology,congress 2008, in Mu...
(Date:9/3/2008)... Third Clinical Trial Reconfirms Strong Evidence...ow Have Lasting Effect on Joints Following Cessati...BOKEN, N.J., Sept. 3 /- According to ...is, the most common type of arthritis,is on the r...f Phytotherapy,Research, reveals Pycnogenol(R), ba...
(Date:9/2/2008)... NEW YORK, Sept. 3 /- ...torios Almirall, S.A. today announced results from...e, a novel long-acting,inhaled anticholinergic for...e pulmonary disease (COPD). In both the ACCLAIM/CO...acy and Safety In Moderate to,Severe COPD Patients...
(Date:9/2/2008)... September is Prostate Cancer Awa... /- September is,Prostate Cancer Awar...nd,Palm Beach announce a revolutionary new way to ...atment courses of radiation. Prostate cancer is,th...US., Morse CyberKnife CEO, James G. Schwade, M.D....
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6AMIA Announces Partnership with CDC to Enhance Public Health Informatics 3573 1AMIA Announces Partnership with CDC to Enhance Public Health Informatics 3573 2Turn Competitive Intelligence into a Competitive Edge 3571 1Turn Competitive Intelligence into a Competitive Edge 3571 2Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission 3569 1Experts Offer Answers on Colonoscopy Options 3567 1Experts Offer Answers on Colonoscopy Options 3567 2...E)--Jun 26, 2007 - Acceleron Pharma,Inc., a bioph...he,treatment of musculoskeletal, metabolic and can...nstrating that ACE-011, a,novel anabolic bone agen...ass and architecture in a murine model of multiple...ma cells in the bone marrow,that disrupts normal b...
...orted Safety & Tolerability Profile,in Subject...ICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Pha...ing of the American Diabetes,Association demonstra...eptidase-4 (DPP-4) in development by Bristol-Myers...ith metformin,exhibited a statistically significa...
Other Medicine Technology:ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical,Model 2ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical,Model 3Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 2Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 3Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 4Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 5Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 6VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
Medicine Products: